OncLive TV

Katie Kerrigan, MD, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer.

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

Andreas Kaubisch, MD, discusses available treatment options for hepatocellular carcinoma.

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

Anthony R. Mato, MD, MSCE, discusses the introduction of rituximab biosimilars in chronic lymphocytic leukemia.

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Imad Tabbara, MD, discusses available treatment options for transplant-eligible and -ineligible patients with multiple myeloma.

Sarah Ferguson, MD, discusses how the results from the LACC trial, which compared minimally invasive surgery with open surgery in patients with IA1, IA2, or IB1 cervical cancer, are impacting surgery in the cervical cancer field.

Ghassan K. Abou-Alfa, MD, discusses the results of the phase III ClarIDHy trial in advanced cholangiocarcinoma.

Susan Domchek, MD, discusses the results of the phase II MEDIOLA trial in germline BRCA-mutated metastatic breast cancer.

Tony S. K. Mok, MD, BMSc, FRCPC, discusses overall survival from the phase III ALEX trial in ALK-positive lung cancer.

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses the rationale for the posthoc analysis of the phase III ARROW study in multiple myeloma.

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

Katie Kerrigan, MD, discusses remaining challenges in the treatment of patients with ROS1-positive non–small cell lung cancer.

Nabil F. Saba, MD, FACP, discusses the potential benefit of immunotherapy in combination with radiation in head and neck cancer.

Shaji K. Kumar, MD, discusses the takeaways from the phase III BELLINI trial which tested venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

James Mohler, MD, discusses what information should be included in a family history, based on the updated National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.

Hope S. Rugo, MD, discusses the rationale for the phase II ELAINE study with lasofoxifene in patients with ESR1-mutated, estrogen receptor–positive, HER2-negative metastatic breast cancer.

Ivan M. Borrello, MD, discusses the current multiple myeloma treatment paradigm.

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the design and findings of the phase Ib BISCAY trial in platinum-refractory urothelial cancer.

Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the results of the phase II/III BFAST trial in patients with ALK-positive lung cancer.

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, and professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses anticipated research in head and neck cancer.

William Eward, MD, DVM, discusses the approval of pexidartinib to treat patients with tenosynovial giant cell tumor.

Massimo Cristofanilli, MD, discusses adverse events caused by the use of aromatase inhibitors in breast cancer.

Clarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.